|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Beiki O, Hall P, Ekbom A and Moradi T:
Breast cancer incidence and case fatality among 4.7 million women
in relation to social and ethnic background: A population-based
cohort study. Breast cancer Res. 14:R52012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: Breast cancer version 2.2015. J Natl Compr Canc
Netw. 13:448–475. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carey LA: Directed therapy of subtypes of
triple-negative breast cancer. Oncologist. 16 (Suppl 1):S71–S78.
2011. View Article : Google Scholar
|
|
6
|
Irvin WJ Jr and Carey LA: What is
triple-negative breast cancer? Eur J Cancer. 44:2799–2805. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adamo V, Ricciardi GR, De Placido S,
Colucci G, Conte P, Giuffrida D, Gebbia N, Masci G, Cognetti F,
Dondi D and Venturini M: Management and treatment of
triple-negative breast cancer patients from the NEMESI study: An
Italian experience. Eur J Cancer. 48:642–647. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bianchini G, Balko JM, Mayer IA, Sanders
ME and Gianni L: Triple-negative breast cancer: Challenges and
opportunities of a heterogeneous disease. Nat Rev Clin Oncol.
13:674–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hudis CA and Gianni L: Triple-negative
breast cancer: An unmet medical need. Oncologist. 16 (Suppl
1):S1–S11. 2011. View Article : Google Scholar
|
|
10
|
Hon JD, Singh B, Sahin A, Du G, Wang J,
Wang VY, Deng FM, Zhang DY, Monaco ME and Lee P: Breast cancer
molecular subtypes: From TNBC to QNBC. Am J Cancer Res.
6:1864–1872. 2016.PubMed/NCBI
|
|
11
|
Buonamici S, Chakraborty S, Senyuk V and
Nucifora G: The role of EVI1 in normal and leukemic cells. Blood
Cells Mol Dis. 31:206–212. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tanaka M, Suzuki HI, Shibahara J, Kunita
A, Isagawa T, Yoshimi A, Kurokawa M, Miyazono K, Aburatani H,
Ishikawa S and Fukayama M: EVI1 oncogene promotes KRAS pathway
through suppression of microRNA-96 in pancreatic carcinogenesis.
Oncogene. 33:2454–2463. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deng X, Cao Y, Liu Y, Li F, Sambandam K,
Rajaraman S, Perkins AS, Fields AP, Hellmich MR, Townsend CM Jr, et
al: Overexpression of Evi-1 oncoprotein represses TGF-β signaling
in colorectal cancer. Mol Carcinog. 52:255–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang H, Schaefer T, Konantz M, Braun M,
Varga Z, Paczulla AM, Reich S, Jacob F, Perner S, Moch H, et al:
Prominent oncogenic roles of EVI1 in breast carcinoma. Cancer Res.
77:2148–2160. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hou A, Zhao L, Zhao F, Wang W, Niu J, Li
B, Zhou Z and Zhu D: Expression of MECOM is associated with
unfavorable prognosis in glioblastoma multiforme. Onco Targets
Ther. 9:315–320. 2016.PubMed/NCBI
|
|
16
|
Koos B, Bender S, Witt H, Mertsch S,
Felsberg J, Beschorner R, Korshunov A, Riesmeier B, Pfister S,
Paulus W and Hasselblatt M: The transcription factor evi-1 is
overexpressed, promotes proliferation, and is prognostically
unfavorable in infratentorial ependymomas. Clin Cancer Res.
17:3631–3637. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Queisser A, Hagedorn S, Wang H, Schaefer
T, Konantz M, Alavi S, Deng M, Vogel W, von Mässenhausen A,
Kristiansen G, et al: Ecotropic viral integration site 1, a novel
oncogene in prostate cancer. Oncogene. 36:1573–1584. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yasui K, Konishi C, Gen Y, Endo M, Dohi O,
Tomie A, Kitaichi T, Yamada N, Iwai N, Nishikawa T, et al: EVI1, a
target gene for amplification at 3q26, antagonizes transforming
growth factor-β-mediated growth inhibition in hepatocellular
carcinoma. Cancer Sci. 106:929–937. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang TY, Huang YP and Ma P: Correlations
of common polymorphism of EVI-1 gene targeted by miRNA-206/133b
with the pathogenesis of breast cancer. Tumour Biol. 35:9255–9262.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Patel JB, Appaiah HN, Burnett RM,
Bhat-Nakshatri P, Wang G, Mehta R, Badve S, Thomson MJ, Hammond S,
Steeg P, et al: Control of EVI-1 oncogene expression in metastatic
breast cancer cells through microRNA miR-22. Oncogene.
30:1290–1301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brooks DJ, Woodward S, Thompson FH, Dos
Santos B, Russell M, Yang JM, Guan XY, Trent J, Alberts DS and
Taetle R: Expression of the zinc finger gene EVI-1 in ovarian and
other cancers. Br J Cancer. 74:1518–1525. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu YC, Chen CN, Wang B, Hsu WM, Chen ST,
Chang KJ, Chang CC and Lee H: Changes in tumor growth and
metastatic capacities of J82 human bladder cancer cells suppressed
by down-regulation of calreticulin expression. Am J Pathol.
179:1425–1433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lwin ZM, Guo C, Salim A, Yip GW, Chew FT,
Nan J, Thike AA, Tan PH and Bay BH: Clinicopathological
significance of calreticulin in breast invasive ductal carcinoma.
Mod Pathol. 23:1559–1566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Erić-Nikolić A, Milovanović Z, Sánchez D,
Pekáriková A, Dzodić R, Matić IZ, Tučková L, Jevrić M, Buta M,
Rašković S and Juranić Z: Overexpression of calreticulin in
malignant and benign breast tumors: Relationship with humoral
immunity. Oncology. 82:48–55. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sheng W, Chen C, Dong M, Zhou J, Liu Q,
Dong Q and Li F: Overexpression of calreticulin contributes to the
development and progression of pancreatic cancer. J Cell Physiol.
229:887–897. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chiang WF, Hwang TZ, Hour TC, Wang LH,
Chiu CC, Chen HR, Wu YJ, Wang CC, Wang LF, Chien CY, et al:
Calreticulin, an endoplasmic reticulum-resident protein, is highly
expressed and essential for cell proliferation and migration in
oral squamous cell carcinoma. Oral Oncol. 49:534–541. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Peng RQ, Chen YB, Ding Y, Zhang R, Zhang
X, Yu XJ, Zhou ZW, Zeng YX and Zhang XS: Expression of calreticulin
is associated with infiltration of T-cells in stage IIIB colon
cancer. World J Gastroenterol. 16:2428–2434. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kallel I, Rebai M, Khabir A and Rebaï A:
What common biomarkers characterize a triple-negative profile in
breast cancer? Pathol Biol (Paris). 63:224–229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ali AM, Ansari JAK, El-Aziz NMA, Abozeed
WN, Warith AMA, Alsaleh K and Nabholtz JM: Triple negative breast
cancer: A tale of two decades. Anticancer Agents Med Chem.
17:491–499. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu N, Zhang J, Zhao J, Mu K, Zhang J, Jin
Z, Yu J and Liu J: Precision medicine based on tumorigenic
signaling pathways for triple-negative breast cancer. Oncol Lett.
16:4984–4996. 2018.PubMed/NCBI
|
|
31
|
Israel BB, Tilghman SL, Parker-Lemieux K
and Payton-Stewart F: Phytochemicals: Current strategies for
treating breast cancer. Oncol Lett. 15:7471–7478. 2018.PubMed/NCBI
|
|
32
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aeffner F, Wilson K, Martin NT, Black JC,
Hendriks CL, Bolon B, Rudmann DG, Gianani R, Koegler SR, Krueger J
and Young GD: The gold standard paradox in digital image analysis:
Manual versus automated scoring as ground truth. Arch Pathol Lab
Med. 141:1267–1275. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang CJ, Zhou ZG, Holmqvist A, Zhang H, Li
Y, Adell G and Sun XF: Survivin expression quantified by Image
Pro-Plus compared with visual assessment. Appl Immunohistochem Mol
Morphol. 17:530–535. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Quan Y, Huang X and Quan X: Expression of
miRNA-206 and miRNA-145 in breast cancer and correlation with
prognosis. Oncol Lett. 16:6638–6642. 2018.PubMed/NCBI
|
|
36
|
Lv Y, Song G and Li P: Correlation of
SOCS-1 gene with onset and prognosis of breast cancer. Oncol Lett.
16:383–387. 2018.PubMed/NCBI
|
|
37
|
Synnestvedt M, Borgen E, Russnes HG, Kumar
NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM and Naume B:
Combined analysis of vascular invasion, grade, HER2 and Ki67
expression identifies early breast cancer patients with
questionable benefit of systemic adjuvant therapy. Acta Oncol.
52:91–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen CN, Chang CC, Su TE, Hsu WM, Jeng YM,
Ho MC, Hsieh FJ, Lee PH, Kuo ML, Lee H and Chang KJ: Identification
of calreticulin as a prognosis marker and angiogenic regulator in
human gastric cancer. Ann Surg Oncol. 16:524–533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zamanian M, Qader Hamadneh LA,
Veerakumarasivam A, Abdul Rahman S, Shohaimi S and Rosli R:
Calreticulin mediates an invasive breast cancer phenotype through
the transcriptional dysregulation of p53 and MAPK pathways. Cancer
Cell Int. 16:562016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Meng L, Wang TY, Li XX and Ma P: Effects
of miR-206/miR-1 on breast cancer stem cell proliferation and the
mechanism. J China Med Univ. 44:394–399. 2015.
|
|
41
|
Frank GA, Danilova NV, Andreeva IuIu and
Nefedova NA: WHO classification of tumors of the breast, 2012. Arkh
Patol. 75:53–63. 2013.(In Russian). PubMed/NCBI
|
